Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.32 |
| ▸ | HTR3B | O95264 | 2/20 | 0.32 |
| ▸ | HTR3A | P46098 | 2/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5731936 | 1.00 | MEN1 (0.34) | MEN1KMT2ASLC6A2SLC6A4CYP2D6 | |
| SCHEMBL538775 | 1.00 | MEN1 (0.34) | MEN1KMT2ASLC6A2SLC6A4CYP2D6 | |
| SCHEMBL13076984 | 0.86 | — | — | |
| SCHEMBL12650558 | 0.84 | MEN1 (0.31) | MEN1KMT2ASLC6A2SLC6A4CYP2D6 | |
| SCHEMBL6057033 | 0.81 | — | — | |
| SCHEMBL10923677 | 0.81 | — | — | |
| Piperazine SCHEMBL4608549 | 0.81 | KDM4E (0.37) | MEN1KMT2A | |
| SCHEMBL17142024 | 0.77 | MEN1 (0.35) | MEN1KMT2ASLC6A2SLC6A4CYP2D6 | |
| SCHEMBL14142190 | 0.76 | SMN1; SMN2 (0.35) | SLC6A2SLC6A4CYP2D6KCNH2SLC6A3 | |
| SCHEMBL13225737 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-20090023747-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
| EP-1899336-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007006714-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006716-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| EP-0527051-B1 | Quinophthalone dyes, ink composition and transfer sheet containing them | MITSUI CHEMICALS INC (JP) | 2000-03-22 | — | — | EP | disclosed |
| US-5387686-A | Sublimable, yellow quinoline derivatives; storage stable; heat light, chemical resistant | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-02-07 | — | — | US | disclosed |
| US-5296445-A | Quinoline dyes | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1994-03-22 | — | — | US | disclosed |
| EP-0527051-A1 | Quinophthalone dyes, ink composition and transfer sheet containing them | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023747-A1 | Cysteine Protease Inhibitors | CTSK, CTSS, CTSZ | MEN1 3090/4885KMT2A 4269/4885SLC6A2 4439/4885 |
| US-20080234260-A1 | Cysteine Protease inhibitors | CTSS, CTSZ, CTSK | MEN1 2218/4885KMT2A 1492/4885SLC6A2 4060/4885 |
| US-20110112089-A1 | Cysteine Protease Inhibitors | CTSS, CTSZ, CTSK | MEN1 2181/4885KMT2A 1689/4885SLC6A2 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.